Drug Detail:Targretin (Bexarotene [ bex-ar-oh-teen ])
Generic Name: BEXAROTENE 75mg
Dosage Form: capsule, liquid filled
Drug Class: Miscellaneous antineoplastics
Drug Detail:Targretin (Bexarotene [ bex-ar-oh-teen ])
Generic Name: BEXAROTENE 75mg
Dosage Form: capsule, liquid filled
Drug Class: Miscellaneous antineoplastics
The recommended initial dose of TARGRETIN is 300 mg/m2/day (see Table 1). TARGRETIN should be taken as a single oral daily dose with a meal. For precautions to prevent pregnancy and birth defects in women of child-bearing potential [see Use in Specific Populations (8.1)].
Initial Dose Level (300 mg/m2/day) |
Number of 75 mg |
|
Body Surface Area (m2) |
Total Daily Dose (mg/day) |
|
0.88 – 1.12 |
300 |
4 |
1.13 – 1.37 |
375 |
5 |
1.38 – 1.62 |
450 |
6 |
1.63 – 1.87 |
525 |
7 |
1.88 – 2.12 |
600 |
8 |
2.13 – 2.37 |
675 |
9 |
2.38 – 2.62 |
750 |
10 |
Dose Modification Guidelines: The 300 mg/m2/day dose level of TARGRETIN may be adjusted to 200 mg/m2/day then to 100 mg/m2/day, or temporarily suspended, if necessitated by toxicity. When toxicity is controlled, doses may be carefully readjusted upward. If there is no tumor response after 8 weeks of treatment and if the initial dose of 300 mg/m2/day is well tolerated, the dose may be escalated to 400 mg/m2/day with careful monitoring.
Duration of Therapy: In clinical trials in CTCL, TARGRETIN was administered for up to 97 weeks.
TARGRETIN should be continued as long as the patient is deriving benefit.